Boostimmune Secures Japanese Patent for Sequence-Independent TCTP Antibody Technology Targeting MDSC Accumulation
Japanese patent granted for technology that inhibits TCTP released from dead tumor cells using antibodies to suppress the accumulation of MDSCs in the tumor microenvironment Granted claims are not expressly limited to specific antibody CDRs or amino acid sequences, but are defined by...
Japanese patent granted for technology that inhibits TCTP released from dead tumor cells using antibodies to suppress the accumulation of MDSCs in the tumor microenvironment Granted claims are not expressly limited to specific antibody CDRs or amino acid sequences, but are defined by...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.